The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

What do we know about the pathology of gray matter in multiple sclerosis

Authors:

Khachanova N.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2): 18‑22

DOI: 10.17116/jnevro201811808218

Read: 2599 times

Download PDF (RU)
Contact the author
Table of contents

WHAT DO WE KNOW ABOUT THE PATHOLOGY OF GRAY MATTER IN MULTIPLE SCLEROSIS
WHAT DO WE KNOW ABOUT THE PATHOLOGY OF GRAY MATTER IN MULTIPLE SCLEROSIS

To cite this article:

Khachanova NV. What do we know about the pathology of gray matter in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2):18‑22. (In Russ.)
https://doi.org/10.17116/jnevro201811808218

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Low-level laser therapy in multiple scle­rosis: justification and opti­mization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56
Glial fibrillary acidic protein: is there a rela­tionship with the course of multiple scle­rosis and traumatic brain injury before the onset of multiple scle­rosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102
Surgical treatment of seco­ndary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209
Quality of life of patients with multiple scle­rosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Abstract:

The emergence of modern methods of immunohistochemistry and further development of MRI has led to a deeper understanding of gray matter (GM) pathology in multiple sclerosis (MS). GM involvement can be extensive including both demyelination (cortical lesions) and neuroaxonal damage. The mechanisms of GM damage in MS remain insufficiently studied. There are two concepts: the lesion of GM is primary and is paralleled by changes in white matter (WM), or secondary, i.e. it is a consequence of the pathological process in WM. More research into GM pathology using the latest MRI techniques will contribute to the understanding of pathological changes in both cortical and subcortical GM.

Keywords:

multiple sclerosis
gray matter
demyelination

Authors:

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Close metadata

References:

  1. Brownell B, Hughes JT. Distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315-320.
  2. Lumsden CE. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, editors. Multiple sclerosis and other demyelinating diseases. Amsterdam: North-Holland Publishing Company; 1970.
  3. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol. 2004;61:226-230.
  4. Benedict RH, Zivadinov R, Carone DA, Weinstock-Guttman B, Gaines J, Maggiore C, Sharma J, Tomassi MA, Bakshi R. Regional lobar atrophy predicts memory impairment in multiple sclerosis. Am J Neuroradiol. 2005;26:1824-1831.
  5. Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker CR, Oschmann P, Kaps M, Vaitl D. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage. 2006;30:891-898.
  6. Ghezzi A, Montanini R, Basso PF, Zaffaroni M, Massimo E, Cazzullo CL. Epilepsy in multiple sclerosis. Eur Neurol. 1990;30:218-223.
  7. Moreau T, Sochurkova D, Lemesle M. Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. Epilepsia. 1998;39:893-896.
  8. Thompson AJ, Kermode AG, Moseley IF, MacManus DG, McDonald WI. Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatry. 1993;56:1317-1320.
  9. Truyen L, Barkhof F, Frequin ST. Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Mult Scler. 1996;1:213-217.
  10. Gilmore CP, Donaldson I, Bo L, Owens T, Lowe J, Evangelou N. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry. 2009;80(2):182-187.
  11. Bø L, Vedeler CA, Nyland H, Trapp BD, Mørk SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003;9(4):323-331.
  12. Albert J, Antel W, Bruck C, Stadelmann. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathology. 2007;17(2):129-138.
  13. Nelson F, Datta S, Garcia N. Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Mult Scler. 2011;17:1122-1129.
  14. Calabrese M, Agosta F, Rinaldi F. Cortical lesions and atrophy associated with cognitive impairment in relapsing- remitting multiple sclerosis. Arch Neurol. 2009;66:1144-1150.
  15. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999;122:17-26.
  16. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neuritis, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389-400.
  17. Bö L, Vedeler CA, Nyland HI, Trapp BD, Mörk SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol. 2003;62:723-732.
  18. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006;67(6):960-967.
  19. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705-2712. https://doi.org/10.1093/brain/awh641
  20. Davydovskaya MV, Boiko AN, Gusev EV. Patologiya serogo veshchestva pri rasseyannom skleroze. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2010;11:66-72.
  21. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 2005;64:1101-1107.
  22. Calabrese M. Imaging distribution and frequency of CLs in patients with multiple sclerosis. Neurology. 2010;75:1234-1240.
  23. Geurts JJ, Bo L, Roosendaal SD, Hazes T, Daniels R, Barkhof F, Witter MP, Huitinga I, van der Valk P. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol. 2007;66(9):819-827.
  24. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, Tribolo A, Capello E, Mancardi GL, Mutani R, Giordana MT, Cavalla P. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol. 2009;68:489-502. https://doi.org/10.1097/NEN.0b013e3181a19a5a
  25. Cohen-Adad J. In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis. Neuroimage. 2011;57:55-62.
  26. Audoin B. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:690-695.
  27. Bö L, Geurts JJG, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol. 2007;64:76-80. https://doi.org/10.1001/archneur.64.1.76
  28. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Bruck W, Rauschka H, Schmidbauer M. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007;17(1):38-44.
  29. Papadopoulos D, Dukes S, Patel R, Nicholas R, Vora A, Reynolds R. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol. 2009;19:238-253.
  30. Dutta R, Chang A, Doud MK. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol. 2011;69:445-454.
  31. Calabrese M, Atzori M, Bernardi V. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol. 2007;254:1212-1220.
  32. Bermel R, Innus MD, Tjoa CW, Bakchi R. Selective caudate atrophy in multiple sclerosis: 3D MRI parcellation study. Neuroreport. 2003;14:335-339.
  33. Cifelli A, Arridge M, Jezzard P. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol. 2002;52:650-653.
  34. Houtchens MK, Benedict RH, Killiany R. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007;69(12):1213-1223.
  35. Henry RG, Shien M, Okuda DT. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiat. 2008;79:1236-1244.
  36. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255-265.
  37. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478-489.
  38. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93:1-12.
  39. Schmidt F, van den Eijnden M, Pescini Gobert R, Saborio GP, Carboni S, Alliod C. Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through systematic genomics approach. PLoS One. 2012;7: 40457.
  40. Torkildsen O, Stansberg C, Angelskar SM, Kooi EJ, Geurts JJ, van der Valk P. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol. 2010;20:720-729.
  41. Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bö L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol. 2005;64(2):147-155.
  42. van Horssen J, Brink BP, de Vries HE, van der Valk P, Bø L. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol. 2007;66(4):321-328.
  43. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Bruck W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-2197.
  44. Howell O. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(9):2755-2759.
  45. Höftberger R. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004;14(1):43-50.
  46. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164-174.
  47. Popescu BF, Bunyan RF, Parisi JE, Ransohoff RM, Lucchinetti CF: A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology. 2011;76(20):1705-1710.
  48. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(4):1089-1104.
  49. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477-493. https://doi.org/10.1002/ana.22230
  50. Calabrese M, Magliozzi R, Ciccarelli O, Geurts J, Reynolds R, Martin R. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci. 2015;16(3):147-158. https://doi.org/10.1038/nrn3900
  51. Fischer MT. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain. 2013;136(6):1799-1815.
  52. Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol. 2010;5(3):271-277.
  53. Ascherio A. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001;286(24):3083-3088.
  54. Levin LI. Multiple sclerosis and Epstein-Barr virus. JAMA. 2003;289(12):1533-1536.
  55. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899-2912.
  56. Serafini B, Muzio L, Rosicarelli B, Aloisi F. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain. 2013;136(7):233.
  57. Magliozzi R. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013;72(1):29-41.
  58. Angelini DF. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9:(4): 1003220.
  59. Lossius A. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8(+) Tcells. Eur J Immunol. 2014;44(11):3439-3452.
  60. Sargsyan SA. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010;74(14):1127-1135.
  61. Willis SN. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132(12):3318-3328.
  62. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology. 2007;68(22 suppl 3):22-31; discussion 43-54.
  63. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques. J Neuropathol Exp Neurol. 2008;67(9):888-899.
  64. Vercellino M. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol. 2007;66(8):732-739.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.